Damage-induced G1 checkpoint in mammalian cells involves upregulation of p53, which activates transcription of p21
p53-inducible cyclin-dependent kinase (CDK) inhibitor p21 (CDKN1A) is the key mediator of damage-induced cell-cycle arrest. p21 interacts with different cyclin/CDK complexes and other regulators of transcription and signal transduction, exerting broad effects on cell survival, gene expression and morphology (Roninson, 2002) . p21 effects are partially mediated by Rb, which is inactivated in proliferating cells through phosphorylation by CDK2 and CDK4/6, both of which are inhibited by p21. As a result, p21 induction leads to Rb dephosphorylation and activation, with ensuing G1 arrest.
Whereas p21 activates Rb by dephosphorylation, several oncoproteins inactivate Rb by degradation via the proteasome. Proteasome-mediated Rb degradation is promoted by Mdm2 (Sdek et al., 2005) and gankyrin (Higashitsuji et al., 2000) , E7 of papilloma virus (Boyer et al., 1996) and Tax of HTLV1 (Kehn et al., 2005) . Oncoprotein-induced proteasomal degradation of Rb is one of the mechanisms for Rb inactivation in carcinogenesis (Ying and Xiao, 2006) , but Rb degradation has not been described in DNA damage response.
Changes in Rb phosphorylation are most commonly detected by immunoblotting through changes in the protein's electrophoretic mobility. Examination of numerous Rb immunoblots published by different groups showed that in many (but not all) cases Rb dephosphorylation, which results from drug treatment, cell senescence or ectopic p21 expression, is associated with a reduction in the Rb protein signal. In the present study, we have asked (i) whether a decrease in the Rb signal in response to p21 reflects protein degradation or merely altered immunoreactivity of dephosphorylated Rb, (ii) if p53 plays a p21-independent role in the decrease in Rb, (iii) whether such decrease can be induced by other CDK inhibitors that induce Rb dephosphorylation and (iv) if the decrease in Rb in drug-damaged cells is dependent on p21 induction.
We have described previously a subline of HT1080 cells, p21-9, which expresses p21 from a promoter inducible by b-galactoside isopropyl-b-thio-galactoside (IPTG) (Chang et al., 1999) . p21 induction in HT1080 p21-9 leads to Rb dephosphorylation and depletion without any changes in Rb mRNA levels (Chang et al., 2000) . As shown in Figure 1a (left lanes), Rb was dephosphorylated and its signal intensity decreased 24-48 h after IPTG addition. To determine if the reduced Rb signal indicates a decrease in protein levels rather than altered antibody reactivity, we have used both a mouse monoclonal and a rabbit polyclonal antibody against Rb. Both antibodies produced the same result ( Figure 1a , left lanes), indicating that the decrease in Rb signal intensity was indeed due to a decrease in the protein level.
The decrease in Rb protein was not accompanied by the appearance of Rb fragments that arise after caspase cleavage of Rb (Tan et al., 1997) . Since the best-known mechanism of Rb degradation is via the proteasome pathway (Ying and Xiao, 2006) , we have tested the effect of a proteasome inhibitor ALLN (N-acetylleucinyl-leucinyl-norleucinal) on p21-induced Rb depletion. In the experiment shown in Figure 1b , cells were treated with IPTG for 20 h with ALLN added in one arm of the experiment for the last 4 h (longer treatment with ALLN could not be used because of the toxicity of this compound). The addition of ALLN did not interfere with Rb dephosphorylation, but reduced the depletion of the protein (Figure 1b) , suggesting that Rb depletion was due to proteasome-mediated degradation.
To determine if p53 contributes to Rb depletion in response to p21, we have analysed the effects of p21 on Rb in HT1080 p21-9 cells, where p53 activity was blocked by GSE56, a transdominant inhibitor of p53 function (Ossovskaya et al., 1996) . p21 induction by IPTG was about twofold lower in the presence of GSE56 ( Figure 1a , right lanes). This inhibition most likely reflects the effect of GSE56 on the p53 response element present in the cytomegalovirus (CMV)-derived promoter, which drives p21 expression in HT1080 p21-9 cells (Chang et al., 1999) . p21 induction in GSE56-expressing cells resulted in complete dephosphorylation and substantial depletion of Rb ( Figure 1a , right lanes). The extent of Rb depletion was somewhat lower in the presence than in the absence of GSE56 ( Figure 1a) ; this modest effect can be accounted for by the lower p21 levels. Hence, p53 is not required for p21-induced Rb depletion in HT1080 cells.
To determine if Rb depletion is a general consequence of its dephosphorylation, we compared the effects of p21 and two other Rb-dephosphorylating CDK inhibitors, p16 Ink4A (CDKN1A), which inhibits CDK4/6, and p27 Kip1 (CDKN2B), which inhibits CDK2. p16 and p27 were expressed in HT1080 cells from an IPTGinducible retroviral vector LNXRO2 (Chang and Roninson, 1996) . IPTG-inducible expression of either p21 or p27 led to Rb dephosphorylation and depletion ( Figure 1c ). In contrast, p16 caused only dephosphorylation but not depletion of Rb. Hence, Rb depletion is not a general consequence of its dephosphorylation.
We have investigated whether Rb depletion in response to DNA damage is determined by p21. Doxorubicin treatment of HT1080 p21-9 cells induced endogenous p21 and led to Rb dephosphorylation and depletion (Figure 2a, left) . We have also analysed this effect in HT1080 p21-9 cells where p53 activity was inhibited by GSE56. As shown in Figure 2a (right), GSE56 blocked p21 induction by doxorubicin almost completely, and under these conditions, Rb showed only minimal dephosphorylation and no depletion. To verify that this effect of GSE56 was directly attributable to p21, we developed a derivative of HT1080 cells with (Chang et al., 1999 ) (left lanes) or HT1080 p21-9 transduced with p53 inhibiting peptide GSE56 (right lanes) after the addition of 50 mM IPTG (Sigma, St Louis, MO, USA). GSE56 (Ossovskaya et al., 1996) was introduced into HT1080 p21-9 cells via a retroviral vector LXSE (Kandel et al., 1997) ; the transduced cells were selected by flow sorting for green fluorescent protein fluorescence. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% FC2 serum. Immunoblotting was carried out by standard procedures, using p21 mouse monoclonal antibody (Oncogene Research, San Diego, CA, USA) (top row), Rb rabbit polyclonal antibody (Neomarkers, Flemont, CA, USA) (middle row) and Rb mouse monoclonal antibody (BD PharMingen, San Diego, CA, USA) (bottom row). a-Tubulin detected with a monoclonal antibody from Sigma was used as a loading control. Immunoblots were developed with horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences, Piscataway, NJ, USA) and ECL chemiluminescence agent (Pierce, Rockford, IL, USA). Phosphorylated ( þ P) and dephosphorylated (ÀP) forms of Rb are marked with arrows. (Chang and Roninson, 1996) is shown. The ratio of Rb to a-tubulin signals, as measured by densitometry using Bio-Rad Versa Doc, is shown at the bottom. p21 regulates Rb degradation EV Broude et al tetracycline/doxycycline-regulated expression of short hairpin RNA (shRNA) against p21. shRNA induction by doxycycline in this cell line (designated HT1080-p21shRNA) partially decreased p21 induction by doxorubicin (Figure 2b ). The remaining levels of p21 were still sufficient to produce Rb dephosphorylation, but the cellular level of dephosphorylated Rb was much higher than that without p21 knockdown (Figure 2b ). These observations indicate that p21 mediates both dephosphorylation and depletion of Rb in response to DNA damage.
To determine whether p21-mediated Rb depletion occurs in a different cell type, we investigated the effects of doxorubicin on Rb in HCT116 colon carcinoma cells and in HCT116 derivatives with a homozygous knockout of either p21 or p53 (Waldman et al., 1996; Bunz et al., 1998) . Doxorubicin treatment of parental HCT116 cells led to both dephosphorylation and depletion of Rb (Figure 3a) . The p21À/À line, which expresses p53 but not p21, expressed much higher basal levels of Rb than the wild-type cells, and it showed no Rb dephosphorylation and no decrease in Rb after 2 days of drug treatment, with only a partial decrease on day 3 (Figure 3a) . The p53À/À cell line showed no detectable p21 without drug treatment and only weak p21 induction by doxorubicin (Figure 3a) . In p53À/À cells, doxorubicin caused substantial dephosphorylation of Rb, but Rb levels were essentially unchanged (Figure 3a) . This suggests that low levels of p21 induced by the drug in p53À/À cells were sufficient to produce partial dephosphorylation of Rb but not Rb depletion.
We next compared doxorubicin with other DNAinteracting agents that differ in their ability to induce p21. Doxorubicin (50 and 200 nM) and ionizing radiation (6 Gy) induced both p21 expression and Rb depletion, whereas 25 nM doxorubicin and the DNA replication inhibitor aphidicolin (2.2 nM) produced little or no p21 induction and did not deplete Rb (Figure 3b) . These results confirm the role of p21 in inducing Rb dephosphorylation and degradation in response to DNA damage. (Waldman et al., 1996) (middle lanes) or p53 (clone 379.2) (Bunz et al., 1998) (right lanes), on the indicated days of treatment with 200 nM doxorubicin. b-Actin (monoclonal antibody, Sigma) was used as a control. (b) Immunoblotting of Rb, p53 and p21 in HCT116 cells treated for 2 days with the indicated concentrations of doxorubicin or 2.2 nM aphidicolin, or 2 days after exposure to ionizing radiation (6 Gy).
In summary, we have found that p21 (which inhibits CDK2 and CDK4/6) and p27 (a selective CDK2 inhibitor) cause not only dephosphorylation but also degradation of Rb. The finding that p16 (a selective CDK4/6 inhibitor) does not deplete Rb would at first glance suggest that phosphorylation by CDK2, but not by CDK4/6, protects Rb from proteolytic degradation. However, this interpretation seems unlikely, because cellular expression of p16 was shown to inhibit not only CDK4/6 but also CDK2, by causing reassortment of cyclin-CDK-inhibitor complexes (Jiang et al., 1998) . On the other hand, p21 and p27 are structurally much more similar to each other than to p16 outside their CDK-binding domains, and it is plausible that their interactions with non-CDK proteins are responsible for the degradation of dephosphorylated Rb. This interpretation is also consistent with the observed dephosphorylation but not degradation of Rb in cells expressing low levels of p21 (Figures 2a and 3a) . The requirement for additional events beyond dephosphorylation can explain why the depletion of dephosphorylated Rb is detectable in some, but not all, human cell lines exposed to DNA damage (see, for example, Figure 2 in Smith et al., 1994) .
Rb degradation is likely to be mediated by the proteasome, since it is inhibited by ALLN that has proteasome inhibition as its primary effect (Drexler, 1997) . p21-induced Rb degradation is unlikely to be mediated by Mdm2, because it was not prevented by the inhibition of p53, a positive regulator of Mdm2. Although there is no evidence for a direct binding between p21 and Rb, p21 was reported to be associated with 20S proteasome that also degrades Rb (Sdek et al., 2005) , and it is conceivable that p21 could drive some as yet unidentified Rb-containing multimeric complexes to the proteasome.
The sequence of events, wherein p21 first activates Rb through dephosporylation and then deactivates it through depletion, suggests negative feedback regulation that limits the duration of Rb-mediated checkpoint arrest. It is noteworthy that senescent (permanently arrested) fibroblasts express primarily p16 rather than p21, and p16 does not cause Rb degradation. We note, however, that this pattern is not common to all senescent fibroblast cultures, since some senescent fibroblasts show apparent Rb depletion by immunoblotting (Stein et al., 1999) . In contrast to normal senescent fibroblasts, p21 expression is maintained over a long term in p16-deficient tumor cells rendered senescent by DNA damage (Chang et al., 2002) , and in such cases Rb appears dispensable for long-term maintenance of cell-cycle arrest. p21-mediated transcriptional inhibition of multiple cell-cycle progression genes (Chang et al., 2000) provides one of the mechanisms that can sustain cell-cycle arrest in the absence of Rb, and additional mechanisms will undoubtedly be elucidated in the future.
p21 is almost never mutated in cancers, and its pattern of expression in human tumors is consistent with a role of both a tumor suppressor and an oncogene (Roninson, 2002) . The finding that p21 both activates Rb by dephosporylation and inactivates it by degradation provides another explanation for the dual tumor suppressor/oncogenic functions of p21.
